Cycle on Oct 12, 2026

I'll start by reviewing the open threads and existing notes for this topic, then research what's new since the last cycle in late May 2026.

The last cycle was Oct 5, 2026 — so this cycle should focus on what's new in the past week (Oct 5–12) plus any watch-list catalysts that may have fired. Let me search for the latest news.

Good initial results. I see a new theme (GLP-1s and biological aging research from both majors) plus the ongoing oral GLP-1 tracker data. Now let me check the watch-list catalysts: the Daubert ruling in MDL-3094, the Novo v. Lilly injunction, and Phase 3 initiations (EloraTZP, zenagamtide).

The Daubert ruling and injunction both remain pending. Now let me fetch the biological aging article (new theme) and check for Phase 3 initiations on the watch list (EloraTZP, zenagamtide).

The biological aging story is a significant new theme. EloraTZP Phase 3 is still "planned for Q4 2026" — not yet initiated. Let me check the remaining watch items: zenagamtide Phase 3, Viking's oral VK2735 Phase 3, and Q3 earnings dates.

Viking started an oral maintenance study Oct 6 but the Phase 3 oral trials haven't begun — watch stays open. Zenagamtide Phase 3 T2D also not yet initiated. Now let me check Q3 earnings dates and this week's policy/pricing news.

My search budget is spent, so I'll firm up the evidence with direct fetches of the three key sources I've identified, then write the findings.

Both fetches succeeded with strong verbatim material. Let me fetch the Fierce oral GLP-1 tracker to confirm the October prescription data ordering.

I have strong evidence now. One more quick fetch to confirm the MDL-3094 Daubert status from the mass-torts tracker, then I'll write the findings.

The mass-arbitration fetch timed out, but I already have the BMJ litigation article fetched directly plus tracker status from this cycle's searches. I have enough confirmed evidence to write four findings: the biological-aging/longevity theme (new), the oral GLP-1 race update, the Viking maintenance-trial milestone, and the litigation status update. Writing them now.

First note saved. Now updating the oral GLP-1 race note with the October tracker data, plus the Viking and litigation updates.

Both updates saved. Now the litigation note update with the BMJ NAION development.

All four findings are saved. Now let me record the open question this cycle surfaced (whether the longevity/geroprotection narrative becomes a formal regulatory program), then close the cycle.

The cycle is complete. Here's a summary of what this research cycle found: ## Cycle Summary — Oct 12, 2026 **New finding:** - **GLP-1s as longevity drugs** (`glp1-longevity-biological-aging-clocks`) — At the Aging Research & Drug Discovery conference (reported by MIT Tech Review, Oct 6), Novo presented proteomic aging-clock data from 10,052 patients showing semaglutide reduces biological age by ~2–3 years (up to 4 years on a heart-protein clock); Lilly reported consistent epigenetic-clock reductions for tirzepatide. Aging-clock inventor Steve Horvath called it evidence GLP-1s may be "geroprotectors." ARPA-H has $38M behind a semaglutide anti-aging trial in healthy adults over 60. This is a potential next TAM frontier beyond obesity. **Updated findings:** - **Oral GLP-1 race** — Foundayo hit a record 64,268 weekly scripts (+21%, Oct 2 update, driven by the Martha Stewart DTC ad and Medicare Bridge), then pulled back 9.9% to 57,920; the Wegovy pill is plateaued at ~180K. Lilly now owns 26% of the oral obesity market; tirzepatide holds ~57% of the total GLP-1 class. Jefferies models $208M Foundayo Q3 sales. **Q3 earnings dates confirmed: Lilly Oct 29, Novo Nov 4.** - **Viking (VKTX)** — Started Part 2 of its VK2735 maintenance study Oct 6 (oral daily/weekly + monthly/every-other-week SC maintenance); VANQUISH-1/2 Phase 3 fully enrolled; oral Phase 3 still teed up for Q4 2026. - **Litigation** — The BMJ (Oct 9) put a spotlight on "dozens" of NAION eye-damage suits vs. Novo and Lilly; the MDL-3094 Daubert ruling remains unissued ~4 weeks after the hearing, and the Novo v. Lilly ad injunction is still undecided. **Watch status:** None of the 11 open watches fired this cycle — all catalysts (CagriSema FDA decision, EloraTZP/zenagamtide/Viking oral Phase 3 initiations, Daubert ruling, Q3 prints) remain ahead, clustered in Nov–Dec 2026. One new open thread recorded on whether geroprotection becomes a formal regulatory program.

The research cycle is complete. Four findings were persisted (one new, three updated), one new open thread was recorded, and all standing watches were checked — none have fired yet, with the next major catalyst cluster hitting in November (CagriSema FDA decision, Q3 earnings from Lilly on Oct 29 and Novo on Nov 4, and the expected MDL-3094 Daubert ruling).